Pharmaceuticals

• Press releases
• Country: United States

Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Chairman and CEO Leonard Mazur to host one-on-one business development meetings CRANFORD, N.J., Nov. 11, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of...

• Press releases
• Country: United States

Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

RADIANZ results will inform ATNM-400 clinical development beyond prostate cancer to patients with advanced HER3-expressing solid tumors in multiple cancers Builds on initial first-in-human clinical data in metastatic castration-resistant prostate cancer presented at EANM 2026 and featured...

• Press releases
• Country: United States

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London

RANCHO CUCAMONGA, Calif., Nov. 11, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global...

• Press releases
• Country: United States

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS)

Ionis told investors in July that TRYNGOLZA was "on track" for $100 million to $110 million in 2026 sales. On November 9, it lowered that target to roughly $50 million. NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today cut its full-year TRYNGOLZA...

• Country: Cyprus

LB Pharmaceuticals at Guggenheim conference: a broad antipsychotic push

• Press releases
• Country: United States

Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development

Scientific Advisory Board brings together world-class expertise in prostate cancer, hematologic malignancies, molecular imaging, radiochemistry and clinical development Internationally recognized advisers to support advancement of Actinium's differentiated radioconjugate pipeline across...

• Press releases
• Country: United States

InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics

Shares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026 VANCOUVER, BC, Nov. 6, 2026 /PRNewswire/ -- InMed Pharmaceuticals Inc. (which has changed its name to Mentari Therapeutics, Inc.) (NASDAQ: INM) ("Mentari" or the "Company") today announced the...

• Country: United States

LB Pharmaceuticals GAAP EPS of -$1.79

• Press releases
• Country: United States

Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

SHANGHAI and HANGZHOU, China and BOSTON, Nov. 5, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core...

• Press releases
• Country: United States

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...